European Investor
04 Aug 2026, 14:33
Pfizer Stock Slips 0.54% Despite Higher Revenue Guidance and Strong Product Growth
Pfizer (NYSE: PFE) shares slipped 0.54% on Tuesday despite reporting solid second-quarter results, raising the midpoint of its full-year revenue guidance and highlighting continued momentum from its newer product portfolio and late-stage pipeline.
Second-quarter revenue increased 3% year over year to $15.0 billion, while operational revenue growth reached 1%. Excluding COVID-19 products Comirnaty and Paxlovid, operational revenue grew 5%, supported by strong performance from recently launched and acquired products, which posted 18% operational growth. Pfizer reported a GAAP loss per share of $0.04 and adjusted EPS of $0.77, with reported results impacted by $4.3 billion in non-cash intangible asset impairment charges.
Growth Portfolio Continues to Offset COVID Declines
Pfizer's underlying business continued to strengthen as growth from key products more than offset declining COVID-related sales.
Eliquis revenue benefited from strong global demand and favorable pricing, while Padcev, the Vyndaqel family and Lorbrena all delivered strong growth. Meanwhile, Paxlovid revenue declined 95% and Comirnaty sales fell 34% as pandemic-related demand continued to normalize.
The company also emphasized continued progress in its obesity and oncology businesses, alongside several expected pivotal clinical readouts over the next 12 months.
Guidance Raised While Cost Savings Expand
Reflecting stronger-than-expected demand for non-COVID products, Pfizer raised the midpoint of its 2026 revenue guidance by $500 million to a range of $60.5 billion to $62.5 billion.
The company reaffirmed its adjusted EPS guidance of $2.80 to $3.00 despite absorbing an expected $0.10 per-share impact from its Innovent Biologics transaction. Pfizer also announced an additional $2.5 billion in anticipated productivity savings to be realized between 2027 and 2029 as part of its ongoing efficiency initiatives.
What to Watch
Despite the modest decline in the stock, investors were encouraged by Pfizer's improving underlying business performance and higher revenue outlook. Going forward, markets will closely monitor continued growth from its non-COVID portfolio, execution of its productivity initiatives, progress in obesity and oncology programs, and upcoming late-stage clinical trial results that could support the company's next phase of growth.
Pfizer (NYSE: PFE) shares slipped 0.54% on Tuesday despite reporting solid second-quarter results, raising the midpoint of its full-year revenue guidance and highlighting continued momentum from its newer product portfolio and late-stage pipeline.
Second-quarter revenue increased 3% year over year to $15.0 billion, while operational revenue growth reached 1%. Excluding COVID-19 products Comirnaty and Paxlovid, operational revenue grew 5%, supported by strong performance from recently launched and acquired products, which posted 18% operational growth. Pfizer reported a GAAP loss per share of $0.04 and adjusted EPS of $0.77, with reported results impacted by $4.3 billion in non-cash intangible asset impairment charges.
Growth Portfolio Continues to Offset COVID Declines
Pfizer's underlying business continued to strengthen as growth from key products more than offset declining COVID-related sales.
Eliquis revenue benefited from strong global demand and favorable pricing, while Padcev, the Vyndaqel family and Lorbrena all delivered strong growth. Meanwhile, Paxlovid revenue declined 95% and Comirnaty sales fell 34% as pandemic-related demand continued to normalize.
The company also emphasized continued progress in its obesity and oncology businesses, alongside several expected pivotal clinical readouts over the next 12 months.
Guidance Raised While Cost Savings Expand
Reflecting stronger-than-expected demand for non-COVID products, Pfizer raised the midpoint of its 2026 revenue guidance by $500 million to a range of $60.5 billion to $62.5 billion.
The company reaffirmed its adjusted EPS guidance of $2.80 to $3.00 despite absorbing an expected $0.10 per-share impact from its Innovent Biologics transaction. Pfizer also announced an additional $2.5 billion in anticipated productivity savings to be realized between 2027 and 2029 as part of its ongoing efficiency initiatives.
What to Watch
Despite the modest decline in the stock, investors were encouraged by Pfizer's improving underlying business performance and higher revenue outlook. Going forward, markets will closely monitor continued growth from its non-COVID portfolio, execution of its productivity initiatives, progress in obesity and oncology programs, and upcoming late-stage clinical trial results that could support the company's next phase of growth.
